The primary composite endpoint was the objective response rate (ORR), defined according to RECIST 1.1 criteria or as a reduction of at least 50% in PSA levels or a confirmed reduction in the circulating tumor-cell count from 5 or more cells to less than 5 cells per 7.5 ml of blood [15]. Here, KLK3 is linked to neoplasm.